Australia's most trusted
source of pharma news
Monday, 08 December 2025
Posted 8 December 2025 AM
MSD is having another tilt at getting a recommendation from the PBAC for a multi-cancer listing for Keytruda for advanced and metastatic cancers at the December intracycle meeting.
"MSD looks forward to the PBAC assessing a revised multi-cancer funding proposal for Keytruda at the December Intracycle meeting," MSD Australia & New Zealand Managing Director, Chifumi Umeda, said.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.